US WorldMeds Launches Final Phase III Trial to Study Myobloc Injections to Treat Drooling

Share

(November 20, 2013) - US WorldMeds, LLC, has launched a final phase III clinical trial to investigate the use of Myobloc (rimabotulinumtoxinB) injection to treat sialorrhea, commonly known as “drooling.” This “drooling” is common in patients who may have difficulty swallowing due to neurological disorders such as Parkinson’s disease, Lou Gehrig’s disease, stroke, brain injury, and cerebral palsy. Read more…

Click for a printer friendly version

Back to top